TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Vaccine development to drive JCI’s Q4 performance: Analysts

  • Yunindita Prasidya

    The Jakarta Post

PREMIUM
Jakarta   /   Wed, October 7, 2020   /  07:43 am
The Jakarta Post Image
Employees pass a screen displaying stock movements at the Indonesia Stock Exchange building in Jakarta on March 11, 2020.(Antara/Galih Pradipta)

The performance of the Jakarta Composite Index (JCI), the main gauge of the local stock exchange, in the fourth quarter hinges on vaccine developments, analysts have said, as the progress of the COVID-19 pandemic remains an important driver of the index’ movement. Despite several tailwinds supporting the JCI’s outlook in the second half of the year, volatility will remain, at least until a vaccine has been approved, Bank Negara Indonesia (BNI) Sekuritas said. “All boils down to vaccine approval. We maintain our view that the approval for population use could be secured in the fourth quarter of this year or the first quarter of next year,” BNI Sekuritas research head Kim Kwie Sjamsudin told The Jakarta Post over a text message on Monday.  The firm expected the eventual approval would materially prop up the global market as the effective and safe vacci...